Spotlight Therapeutics develops cell-targeted in vivo CRISPR gene-editing biologics using its proprietary TAGE (Targeted Active Gene Editors) platform. TAGE comprises highly engineered, modular programmable CRISPR effectors designed to target and edit selected cell types in vivo, avoiding the complexity of viral, viral-like, and nanoparticle delivery systems. The approach aims to expand applications and increase patient access, with the aspiration of enabling effective one-and-done medicines. Spotlight is advancing a pipeline toward clinical studies with programs in immuno-oncology, ophthalmic diseases, and hemoglobinopathies. Founded in mid-2018 and headquartered in Hayward, California, the company announced a $36.5M Series B to fund progression toward the clinic. Recent promotions and executive hires (CSO, Executive Director of Technology, VP Corporate and Business Development) support its push to execute development plans and establish strategic partnerships. Spotlight Therapeutics develops programmable CRISPR ribonucleoproteins (RNPs) and a proprietary TAGE platform to enable direct in vivo, cell-targeted gene editing using a modular biologics approach. The platform is designed to avoid complexities and toxicities associated with cell, viral, and nanoparticle delivery methods. The company is advancing lead programs in hemoglobinopathies and immuno-oncology toward clinical studies. Spotlight emphasizes integrating CRISPR editing with established biologics precepts to expand therapeutic applications. Leadership includes CEO Mary Haak-Frendscho and industry veterans Mary Janatpour and Hari Jayaram, and the company was co-founded by Alex Marson, Jacob Corn, and Patrick Hsu. Its scientific advisory board features Carolyn Bertozzi, Ronald Levy, and Jim Wells. Spotlight is headquartered in Hayward, California and was established in mid-2018. The company recently completed a financing round to support its pipeline advancement.

Total raised

$37M

Funding rounds

2

Latest round

Series B

Latest activity

Mar 2022